Why FISH for ALK Testing (and PCR for EGFR and KRAS) in NSCLC?
Description: Aurelia Meloni-Ehrig, PhD discussed current mutation testing guidelines and best practices for patients with NSCLC, compares and contrasts ALK testing methodologies and discusses the advantages offered by FISH for ALK mutation status testing.
• Describe genetic aberrations (eg, EGFR, KRAS, ALK) associated with patients with NSCLC and the impact they have on individualized disease management
• Communicate current guidelines and best practices for NSCLC mutation testing
• Discuss the potential clinical benefits associated with ordering an NSCLC-specific mutation panel, rather than individual assays
• Compare and contrast ALK testing methodologies and communicate the advantages offered by FISH